scholarly journals In Vitro Activity of Plant Extracts and Alkaloids against Clinical Isolates of Extended-Spectrum b-Lactamase (ESBL)-Producing Strains

Molecules ◽  
2011 ◽  
Vol 16 (7) ◽  
pp. 5453-5459 ◽  
Author(s):  
Guo-Ying Zuo ◽  
Fan-Yan Meng ◽  
Jun Han ◽  
Xiao-Yan Hao ◽  
Gen-Chun Wang ◽  
...  
Keyword(s):  
Plant Extracts ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Extended Spectrum

In vitro activity of β-lactam and non–β-lactam antibiotics in extended-spectrum β-lactamase–producing clinical isolates of Escherichia coli

2006 ◽  
Vol 54 (2) ◽  
pp. 135-139 ◽  
Author(s):  
Antonio Sorlózano Puerto ◽  
José Gutiérrez Fernández ◽  
Juan de Dios Luna del Castillo ◽  
María José Soto Pino ◽  
Gonzalo Piédrola Angulo
Keyword(s):  
Escherichia Coli ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Extended Spectrum

scholarly journals In Vitro Activity of Ceftolozane-Tazobactam against Enterobacter cloacae Complex Clinical Isolates with Different β-Lactam Resistance Phenotypes

2018 ◽  
Vol 62 (9) ◽  
Author(s):  
Frédéric Robin ◽  
Michel Auzou ◽  
Richard Bonnet ◽  
Romain Lebreuilly ◽  
Christophe Isnard ◽  
...  
Keyword(s):  
Enterobacter Cloacae ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Wild Type ◽  
Content Type ◽  
Extended Spectrum ◽  
Enterobacter Cloacae Complex

ABSTRACT The study evaluated the in vitro activity of ceftolozane-tazobactam (C/T) against 94 unique clinical isolates of Enterobacter cloacae complex (ECC). No difference was observed according to the ECC cluster. The in vitro activity greatly varied depending on the β-lactamase-producing profile: 100%, 67%, and 19% of wild-type, extended-spectrum β-lactamase (ESBL)-producing, and AmpC-overproducing strains, respectively, were susceptible to C/T. The use of C/T could be of interest for the treatment of some infections caused by ESBL-producing AmpC-nonoverexpressing ECC isolates.

In vitro activity of tigecycline against extended-spectrum β-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study

2011 ◽  
Vol 70 (2) ◽  
pp. 270-273 ◽  
Author(s):  
Jesus Silva-Sanchez ◽  
Fernando Reyna-Flores ◽  
Ma. Elena Velazquez-Meza ◽  
Teresa Rojas-Moreno ◽  
Arturo Benitez-Diaz ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Multicentric Study ◽  
Extended Spectrum

scholarly journals 1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S655-S655
Author(s):  
Daniel Navas ◽  
Angela Charles ◽  
Amy Carr ◽  
Jose Alexander
Keyword(s):  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Resistance Testing ◽  
Clinical Samples ◽  
In Vitro Activity ◽  
Carbapenemase Gene ◽  
Resistant Strains

Abstract Background The activity of imipenem/relebactam (I/R), ceftazidime/avibactam (CZA) and cefiderocol (FDC) were evaluated against clinical isolates of multidrug resistant (MDR) strains of P. aeruginosa which was resistant to ceftolozane/tazobactam (C/T). The recent increase of MDR P. aeruginosa strains isolated from clinical samples has prompted research and development of new antimicrobials that can withstand its multiple resistance mechanisms. C/T is an effective option for treatment of MDR P. aeruginosa in our facility with only 10% of resistance in MDR strains, but the emergence of resistance may occur due to the presence of a carbapenemase gene or an ampC mutation. Methods Antimicrobial susceptibility testing for C/T Etest® (bioMérieux, Inc.) were performed on all MDR strains initially screened by the VITEK2® (bioMérieux, Inc.). 10% (n=20) of all MDR isolates were resistant to C/T by the CLSI 2019 breakpoints. These resistant isolates were tested for presence of a carbapenemase gene using the GeneXpert CARBA-R (Cepheid®) PCR and against CZA Etest® (bioMérieux, Inc.) I/R gradient strips (Liofilchem®) and FDC broth microdilution (Thermo Scientific™ Sensititre™). Results A total of 20 clinical isolates of MDR P. aeruginosa resistant to C/T were tested following standardized CLSI protocols and techniques. All 20 isolates were screened for the presence of a carbapenemase gene (blaVIM, blaNDM, blaKPC, blaOXA-48, blaIMP). A blaVIM gene was detected in 6 (30%) out of 20 isolates. FDC demonstrated the greatest activity with 85% (n=17) of susceptible isolates (CLSI MIC <4µg/dL). CZA (CLSI MIC <8µg/dL) and I/R (FDA MIC <2µg/dL) showed 15% (n=3) and 10% (n=2) of susceptible isolates respectively. FDC was active against all 6 blaVIM isolates, where all 6 strains were resistant to CZA and I/R as expected. 3 isolates tested non-susceptible against FDC; additional characterization was not performed at this time. Conclusion Based on these results, FDC demonstrated the greatest in-vitro activity against C/T resistant strains of MDR P. aeruginosa. FDC also demonstrated activity against all 6 MDR P. aeruginosa carrying blaVIM gene. FDC is a strong option to consider on MDR P. aeruginosa strains based on a resistance testing algorithm and a cost/effective protocol. Disclosures All Authors: No reported disclosures

Sign in / Sign up

Export Citation Format

Share Document